FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD)
Drug Manufacturers to Develop Patient Medication Guides
FDA has directed the manufacturers of all drug products approved for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) to develop patient Medication Guides to alert patients to possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, and to advise them of precautions that can be taken.
Note: This page links to PDF files which require the free Adobe Acrobat Reader.
Back to Drug Information
Date created: February 21, 2007,
Updated September 21, 2007